Evaluation of the i-STAT Alinity v in a veterinary clinical setting

Burke, Jasper E.; Nguyen, Thuy Hien; Davis, Tanya D.; Koenig, Amie; Lane, Selena L.; Good, Jennifer; Brainard, Benjamin M.

doi:10.1177/10406387211019710

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identified variables are similar to those identified as prognostic markers in previous studies of acute colitis in horses 2,3,5 . A major strength of these prognostic variables is that they are easily assessed, even under field conditions 28,29 . Preadmission decision making is desirable for several reasons, not least from an animal welfare point of view.…”

Section: Discussionsupporting

confidence: 64%

“…2,3,5 A major strength of these prognostic variables is that they are easily assessed, even under field conditions. 28,29 Preadmission decision making is desirable for several reasons, not least from an animal welfare point of view. The final multivariate model included admission year to adjust for the increase in survival from 48.4% to 80.1% over the study period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum amyloid A does not predict non‐survival in hospitalised adult horses with acute colitis

et al. 2023

View full text Add to dashboard Cite

Background Predicting non‐survival in horses with acute colitis improves early decision making. Therefore, this study aimed to determine the prognostic value of serum amyloid A (SAA) and other clinicopathological and clinical variables in adult horses with acute colitis. Methods Clinical variables, SAA and other blood biomarkers, including plasma L‐lactate (lactate), were assessed in 176 horses with acute colitis. A multivariate model for the prediction of non‐survival was constructed. Icelandic horses were analysed separately. Results Admission SAA was similar in survivors (median 548 mg/L; range 0–5453 mg/L) and non‐survivors (396 mg/L; 0–5294) (p = 0.43). A model for non‐survival included year of admission, lactate, heart rate, age and colic duration of more than 24 hours. Icelandic horses had a relative risk of 2.9 (95% confidence interval = 2.2–3.8) for acute colitis compared to other breeds. Lactate in Icelandic horses was higher than that in other breeds in both survivors (4.0 mmol/L, range 1.0–12.7 vs. 2.0, 0.7–12.5) and non‐survivors (10.0, 1.5–26 vs. 5.4, 0.8–22) (p < 0.001). Limitations The prognostic value of repeated measurements of SAA could not be assessed in this study, as 71% of the non‐surviving horses died within a day of admission. Conclusion Admission SAA did not predict non‐survival. Breed needs consideration when lactate is evaluated as a predictor for non‐survival in horses with colitis.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Serum amyloid A does not predict non‐survival in hospitalised adult horses with acute colitis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…ISEs are robust, reliable, and low-cost systems that can be miniaturized easily, which has made them popular in numerous fields, including environmental, agricultural, and industrial analysis [19]. Besides their commercialization in human healthcare [20], portable blood analyzers that employ ISEs are also commercially available in veterinary clinical applications [21]. A recent fully integrated portable paper microfluidic device for the determination of ions in blood was developed by Jin et al [16].…”

Section: Determination Of Ions Sugars and Metabolites From Bodily Flu...mentioning

confidence: 99%

Microfluidic systems in clinical diagnosis

Lapizco‐Encinas

Zhang

2022

Electrophoresis

View full text Add to dashboard Cite

The use of microfluidic devices is highly attractive in the field of biomedical and clinical assessments, as their portability and fast response time have become crucial in providing opportune therapeutic treatments to patients. The applications of microfluidics in clinical diagnosis and point‐of‐care devices are continuously growing. The present review article discusses three main fields where miniaturized devices are successfully employed in clinical applications. The quantification of ions, sugars, and small metabolites is examined considering the analysis of bodily fluids samples and the quantification of this type of analytes employing real‐time wearable devices. The discussion covers the level of maturity that the devices have reached as well as cost‐effectiveness. The analysis of proteins with clinical relevance is presented and organized by the function of the proteins. The last section covers devices that can perform single‐cell metabolomic and proteomic assessments. Each section discusses several strategically selected recent reports on microfluidic devices successfully employed for clinical assessments, to provide the reader with a wide overview of the plethora of novel systems and microdevices developed in the last 5 years. In each section, the novel aspects and main contributions of each reviewed report are highlighted. Finally, the conclusions and future outlook section present a summary and speculate on the future direction of the field of miniaturized devices for clinical applications.

show abstract

“…Specifically the i-STAT alinity has the ability to perform arterial blood gas analysis (Cg4+) and electrolyte analysis (Chem8) with acceptable performance. 4 These tools in the translational research realm provide a quick and reliable way to perform basic analysis in the management of animals or measurement for end points of care.…”

Section: Introductionmentioning

confidence: 99%